SAN DIEGO, Feb. 17, 2011 /PRNewswire/ -- NexBio, Inc. announced the presentation of "Treatment of Parainfluenza 3 Infection with DAS181 in a Patient after Allogeneic Stem Cell Transplantation" at the American Society for Blood and Bone Marrow Transplant meeting February 17-21 in Honolulu, Hawaii. The data was presented by Dr. Yi-Bin Chen, Department of Medicine, Massachusetts General Hospital and Harvard Medical School.
Parainfluenza virus (PIV) infection causes Influenza-like-Illness (ILI), a common respiratory disease. Parainfluenza can result in significant morbidity and mortality in immunocompromised patients. The current standard treatment for PIV infection is supportive care as there are no approved drugs or vaccines for the infection. DAS181 is an investigational antiviral medication with preclinical activity in vitro and in vivo against PIV and influenza viruses (IFV). The receptor for both PIV and IFV on airway epithelial cells is sialic acid. DAS181, a recombinant sialidase fusion protein, removes sialic acid residues from airway epithelium, thereby preventing both the initial step in PIV and IFV infection and the spread of existing infection. DAS181 is currently being studied in a Phase II clinical trial (http://flugotyoublue.com/) enrolling subjects with ILI in the United States. This study is funded by the National Institute of Allergy and Infectious Disease, National Institutes of Health.
DAS181 was administered to a bone marrow transplant patient who had progressive and worsening PIV-3 infection under an Emergency Investigational New Drug Application, as permitted by the Food and Drug Administration. This is the first reported treatment with DAS181 of a patient with PIV infection after allogeneic stem cell transplantation.
Within one day of initiating treatment, the patient's respiratory status had improved, and by